ADMA Biologics
ADMA
91 hedge funds and large institutions have $140M invested in ADMA Biologics in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 14 reducing their positions, and 10 closing their positions.
193% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 14
170% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 10
41% more call options, than puts
Call options by funds: $1.99M | Put options by funds: $1.41M
23% more funds holding
Funds holding: 74 → 91 (+17)
8% more capital invested
Capital invested by funds: $130M → $140M (+$9.86M)
1.39% more ownership
Funds ownership: 54.73% → 56.11% (+1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$17.5M |
| 2 |
BlackRock
New York
|
+$4.59M |
| 3 |
6CM
683 Capital Management
New York
|
+$4.49M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.49M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$6.17M |
| 2 |
MWVC
Morgens Waterfall Vintiadis & Co
New York
|
-$2.4M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.79M |
| 4 |
Jane Street
New York
|
-$443K |
| 5 |
Millennium Management
New York
|
-$249K |
ADMA Hedge Fund Activity: Q1 2020 in Review
91 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2020, worth a combined $140M — up 7.6% from $130M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ADMA positions and 10 closed out — a net gain of 17 holders — while 41 added to existing stakes and 14 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $17.5M. The largest seller was Consonance Capital Management, cutting an estimated $6.17M.
- 91 institutional investors held ADMA Biologics (ADMA) as of Q1 2020, up from 74 in Q4 2019.
- Funds reported $140M of ADMA Biologics stock for Q1 2020, up 7.6% quarter-over-quarter.
- 27 funds opened new ADMA Biologics positions in Q1 2020 and 10 closed out, a net change of +17 holders.
- The largest ADMA Biologics buyer in Q1 2020 was Perceptive Advisors, an estimated $17.5M added.
- The largest ADMA Biologics seller in Q1 2020 was Consonance Capital Management, an estimated $6.17M sold.
Based on aggregated 13F filings for Q1 2020.